M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
about
Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, RwandaHigh-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimenModelling imperfect adherence to HIV induction therapyLow-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.Residual activity of two HIV antiretroviral regimens prescribed without virological monitoringMolecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failureEffect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibilityRetrovirus reverse transcriptases containing a modified YXDD motif.Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.
P2860
Q28535266-BD04742F-2F55-4401-B12E-5F878FD004D9Q28538692-E58900A2-4534-4C49-800E-73226833E77EQ33523201-93E0CA28-7B1F-4B3F-BE5C-8B451E8A2CB8Q33602033-51EB1B1E-45A1-47E8-A45C-3D2FADCAA41FQ35270968-CF3A68B4-E307-468F-BD02-2F375E17B4B0Q35566910-CA1BAF09-4458-4230-95F9-EA8E0BCA9E1BQ35579833-5A475E45-0B5A-4027-9097-4DC48ACDE934Q35698801-6DDDD588-0EE8-47BF-AE6B-A7597318B5DCQ35941273-8BF4AA92-E066-42FB-B5C8-4510F3F2757BQ36186797-DF592A06-4ED5-468A-ABE3-EFC5F13AAE60Q36836868-266A3C78-1A9E-4B85-B677-13398C57C767Q39564517-6869C2F7-CA05-47F3-B074-E536A9F8503FQ39740543-BAB17480-90BC-496E-A6B4-9E592057DEF1Q40706086-5C5777BF-0382-4DED-A3DE-90EA4EDA974D
P2860
M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
M184V is associated with a low ...... e to zidovudine and stavudine.
@en
M184V is associated with a low ...... e to zidovudine and stavudine.
@nl
type
label
M184V is associated with a low ...... e to zidovudine and stavudine.
@en
M184V is associated with a low ...... e to zidovudine and stavudine.
@nl
prefLabel
M184V is associated with a low ...... e to zidovudine and stavudine.
@en
M184V is associated with a low ...... e to zidovudine and stavudine.
@nl
P2093
P50
P1433
P1476
M184V is associated with a low ...... e to zidovudine and stavudine.
@en
P2093
CNA3002 International Study Team
Chris Stone
Gillian Amphlett
Margaret Tisdale
Mounir Ait-Khaled
Schlomo Staszewski
P304
P356
10.1097/00002030-200208160-00017
P407
P577
2002-08-01T00:00:00Z